Newsroom

Mar 20, 2025

− Novel Mechanism of Action Delivers Rapid Knockdown of Transthyretin, Addressing the Disease at its Source –

− Proven Consistency of Effect on Cardiovascular Outcomes, Function, and Quality of Life in ATTR-CM Population Representative of Today’s Patients –

– Only Therapeutic Approved in the U.S. to Address Both Cardiomyopathy and Polyneuropathy Manifestations of ATTR Amyloidosis −

– Alnylam Offers Multiple Programs to Support Broad and Seamless Patient Access; Majority of Patients Expected to Pay $0 in Out-of-Pocket Costs for AMVUTTRA –

Mystery Solved: New Research Reveals Why a Key Protein Turns Deadly in Aging Bodies
 

By Scripps Research Institute

January 30, 2025

These insights could drive the development of new drugs to treat transthyretin amyloidosis, a progressive and fatal disease.

An Unexpected Benefit of Adding the Patient Voice to Medical Education—Train Providers to Be Better

Mackenzie N. Boedicker, MS, BS & Deborah D. Boedicker, MBA, BS

"Light the Night for Amyloidosis" is an awareness campaign designed to raise awareness about the symptoms, diagnosis, treatment, and potential cure for amyloidosis. In honor of 'Amyloidosis Awareness Month' in March, we're encouraging everyone to light up their porch or entryway with red bulbs throughout the month. You can purchase the bulbs in our shop HERE.